TYRA Stock Forecast 2025-2026
Distance to TYRA Price Targets
TYRA Price Momentum
🤔 Considering Tyra Biosciences (TYRA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest TYRA Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, TYRA has a bullish consensus with a median price target of $30.00 (ranging from $28.00 to $33.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $11.50, the median forecast implies a 160.9% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Biegler at Oppenheimer, projecting a 187.0% upside. Conversely, the most conservative target is provided by Eliana Merle at UBS, suggesting a 143.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TYRA Analyst Ratings
TYRA Price Target Range
Latest TYRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TYRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 18, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $30.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $30.00 |
| Jan 7, 2025 | UBS | Eliana Merle | Buy | Initiates | $28.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $30.00 |
| Oct 29, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $32.00 |
| Oct 28, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $32.00 |
| Oct 25, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $28.00 |
| Oct 18, 2024 | B of A Securities | Geoff Meacham | Buy | Upgrade | $31.00 |
| Oct 7, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $30.00 |
| Sep 19, 2024 | Oppenheimer | Matthew Biegler | Outperform | Maintains | $33.00 |
| Aug 15, 2024 | Piper Sandler | Christopher Raymond | Overweight | Initiates | $33.00 |
| Aug 8, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $28.00 |
| Aug 8, 2024 | Oppenheimer | Matthew Biegler | Outperform | Maintains | $25.00 |
| Jul 3, 2024 | Oppenheimer | Matthew Biegler | Outperform | Reiterates | $28.00 |
| Jul 3, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $23.00 |
| Jul 3, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $28.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $23.00 |
| May 13, 2024 | Oppenheimer | Matthew Biegler | Outperform | Reiterates | $28.00 |
| May 10, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $23.00 |
| May 10, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $28.00 |
Tyra Biosciences Inc. (TYRA) Competitors
The following stocks are similar to Tyra Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tyra Biosciences Inc. (TYRA) Financial Data
Tyra Biosciences Inc. has a market capitalization of $581.93M with a P/E ratio of -7.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -28.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Tyra Biosciences Inc. (TYRA) Business Model
About Tyra Biosciences Inc.
Develops precision therapies for cancer drug resistance.
Tyra Biosciences generates revenue by creating and commercializing small-molecule inhibitors designed to overcome drug resistance in cancer treatments. The company focuses on researching specific gene alterations to develop targeted therapies that improve patient outcomes.
Operating in the competitive biotechnology sector, Tyra Biosciences aims to address unmet medical needs in oncology and potentially other diseases. Their advanced technology and molecular insights position them to contribute significantly to the future of cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Dr. Todd Harris Ph.D.
Country
United States
IPO Year
2021
Website
tyra.bioTyra Biosciences Inc. (TYRA) Latest News & Analysis
Tyra Biosciences (Nasdaq: TYRA) will present at multiple investor conferences, including Oppenheimer and TD Cowen, from February to March 2025, featuring fireside chats and one-on-one meetings.
Tyra Biosciences' participation in key investor conferences highlights its commitment to transparency and engagement, potentially attracting interest and impacting stock performance.
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
1 month agoTyra Biosciences (Nasdaq: TYRA) announced two abstracts accepted for the 2025 ASCO Gastrointestinal Cancers Symposium, highlighting its research in FGFR-targeted therapies.
Tyra Biosciences' acceptance of abstracts at a major cancer symposium highlights its progress and potential in FGFR-targeted therapies, signaling growth opportunities and possible investor interest.
TYRA has appointed Dr. Erik Goluboff as SVP of Clinical Development to lead NMIBC efforts. The first patient for the SURF302 trial is expected to be dosed in Q2 2025.
The appointment of Dr. Goluboff signals a strategic focus on clinical development, potentially enhancing TYRA's pipeline and investor confidence ahead of the SURF302 trial.
Recent insider share purchases have surged as the year-end approaches, indicating potential confidence from company executives in their firms' prospects.
Significant insider share purchases often signal confidence in a company's future performance, potentially indicating undervaluation and driving investor interest.
Tyra Biosciences reported positive interim results for TYRA-300 in mUC, cleared IND for a pediatric study, appointed a new CMO, and had $360.1 million in cash and equivalents as of Q3 2024.
Positive clinical results and new studies for TYRA-300 indicate potential growth in Tyra Biosciences' value, while strong cash reserves suggest financial stability for upcoming projects.
Tyra Biosciences' TYRA-300, an oral FGFR-3 inhibitor, received FDA clearance for a Phase 2 trial in children with achondroplasia, with the first patient expected to be dosed in Q1 2025.
TYRA-300's FDA clearance for Phase 2 trials marks a significant advancement for Tyra Biosciences, potentially boosting its market position and attracting investor interest in the biotech sector.
Frequently Asked Questions About TYRA Stock
What is Tyra Biosciences Inc.'s (TYRA) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Tyra Biosciences Inc. (TYRA) has a median price target of $30.00. The highest price target is $33.00 and the lowest is $28.00.
Is TYRA stock a good investment in 2025?
According to current analyst ratings, TYRA has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TYRA stock?
Wall Street analysts predict TYRA stock could reach $30.00 in the next 12 months. This represents a 160.9% increase from the current price of $11.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tyra Biosciences Inc.'s business model?
Tyra Biosciences generates revenue by creating and commercializing small-molecule inhibitors designed to overcome drug resistance in cancer treatments. The company focuses on researching specific gene alterations to develop targeted therapies that improve patient outcomes.
What is the highest forecasted price for TYRA Tyra Biosciences Inc.?
The highest price target for TYRA is $33.00 from Matthew Biegler at Oppenheimer, which represents a 187.0% increase from the current price of $11.50.
What is the lowest forecasted price for TYRA Tyra Biosciences Inc.?
The lowest price target for TYRA is $28.00 from Eliana Merle at UBS, which represents a 143.5% increase from the current price of $11.50.
What is the overall TYRA consensus from analysts for Tyra Biosciences Inc.?
The overall analyst consensus for TYRA is bullish. Out of 9 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are TYRA stock price projections?
Stock price projections, including those for Tyra Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
